Gamida Cell (GMDA) Stock Jumps After Positive Phase 3 Data

Gamida Cell’s (NASDAQ: GMDA) share price has jumped 19% after the company announced data from its Phase 3 study of omidubicel.

The company said that the drug is an investigational advances cell therapy and could be used as a “potential life-saving treatment option for patients in need of bone marrow transplant.” The study met its primary endpoint as well as all three of its secondary endpoints.

Julian Adams, Ph.D., chief executive officer of Gamida Cell, stated that the additional data “reinforce the potential of omidubicel and move us another step closer toward bringing potentially curative therapies to patients.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Gamida said that they are continuing to work to enable the submission of its biologics license application for omidubicel to the FDA, which is expected in the fourth quarter.

Gamida Cell stock…

Gamida’s share price has jumped premarket on Tuesday since the news was announced. After closing Monday’s session at $4.20, shares are now priced at $4.80, up 14%.

PEOPLE WHO READ THIS ALSO VIEWED:

• Alteryx stock surges after updating Q3 revenue guidance
• Trade stocks with Plus500
• Learn stock trading strategies